**Author details**

Pencho Kossev and Tsvetan Sokolov\*

\*Address all correspondence to: sokolovi2001@abv.bg

Clinic of Orthopedics and Traumatology, MHAT – Rouse, Bulgaria

#### **References**

PRP treatment is widely applied in the last ten years, especially for stimulating coagulation. A number of studies show that platelets demonstrate other functions, too. They are connected to liberating bioactive proteins and growth factors. The bioactive proteins as well as the growth factors improve tissue regeneration and the process of healing. PRP is the first true biologic therapy that has hit orthopedics by storm. Its ease of use and generally high safety profile has made it a preferred option for the most of the physicians and their patients worldwide. When trauma of musculoskeletal system injuries occur healing takes longer periods of time, and frequently they do not recover completely. Fast and effective recovery is of particular impor‐ tance for athletes. That's why all healing methods that accelerate the recovery process are

The administration of PRP in athletes has been gradually introduced in everyday patients. This has become another option for treatment in addition to conservative options. A number of surgical manipulations can influence results in PRP treatment, such as grafts, medication, and

"Following recommendations of the International Olympic Committee (IOC), the local applications of PRP have been used in the treatment of mild to moderate lesions with no

Main indications are acute and chronic wounds, pseudarthrosis, ligament and muscle injuries, some tendinopathies, osteoarthritis, chondral injuries. Almost all the surgeries carried out

PRP represents an autologous biological material as its action is directly related to general clinical conditions of the patient. The particular reason for the appearance of lesions is important in order to select an appropriate treatment method and technical application. However, standardization in PRP protocols and long-term follow-up should clarify some of the questions regarding the durability of these procedures and any possible modification that

Various additional new studies are necessary to further improve the results of PRP application in different pathologies. This will help with understanding the different stages of the healing

process and demonstrate the potential of PRP treatment in everyday patients.

fundamentally important. Many different pathologies can be treated with PRP.

physical therapy.

186 Immunopathology and Immunomodulation

**Author details**

surgical indication, or during surgery" [107].

should be done to achieve better results.

Pencho Kossev and Tsvetan Sokolov\*

\*Address all correspondence to: sokolovi2001@abv.bg

Clinic of Orthopedics and Traumatology, MHAT – Rouse, Bulgaria

since 2007 have used PRP, whether in gel or liquid form [108].


Trends Biotechnol. 2009;27(3):158–167 DOI: 10.1016/j.tibtech.2008.11.009. Epub 2009 Jan 31.

[28] Perez AGM, Lana JF, Rodrigues AA, Luzo ACM, Belangero WD, Santana MHA. Challenges and a Feasible Strategy for Studies and Standardization of Platelet-Rich Plasma. In: Lana JF (ed), Platelet-Rich Plasma Regenerative Medicine: Sports Medi‐ cine, Orthopedic, and Recovery of Musculoskeletal Injuries, Springer. 2014;119-136. DOI: 10.1007/978-3-642-40117-6.

[14] Herr AB, Farndale RW. Structural insights into the interactions between platelet re‐ ceptors and fibrillar collagen. J Biol Chem. 2009;284(30):19781–19785. DOI: 10.1074/

[15] Mehta S, Watson JT. Platelet-rich concentrate: Basic science and current clinical appli‐ cation J Orthop Trauma. 2008;22(6):433-438. DOI: 10.1097/BOT.0b013e31817e793f. [16] Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechani‐

[17] Clemetson KJ, Clemetson JM. Platelet receptors. In: Michelson AD (ed) Platelets, 2nd

[18] Cognasse F, Hamzeh-Cognasse H, Lafarge S, Delezay O, Pozzetto B, McNicol A, Gar‐ raud O. Toll-like receptor 4 ligand can differentially modulate the release of cyto‐ kines by human platelets. Br J Haematol. 2008;141(1):84–91. DOI:10.1111/j.

[19] Blair P, Flaumenhaft R. Platelet alpha-granules: Basic biology and clinical correlates. Blood Rev. 2009;23(4):177–189. DOI: 10.1016/j.blre.2009.04.001. Epub 2009 May 17. [20] Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):13–33. DOI: 10.1160/THS10-11-0720. Epub 2011 Apr 11.

[21] Villela DL, et al. Topical therapy of chronic leg ulcers with platelet-rich plasma: A systematic review of the literature. Paper present at: WOCN 2010 Conference of the

[22] Dellinger R, Britton C. Autologous platelet grafting procedure—a new approach to healing chronic wounds and comparison between current therapies. Monograph

[23] Marx RE. Platelet-rich plasma (PRP): What is PRP and what is not PRP? Implant

[24] Weglein A, Sampson S,Aufiero D. Platelet-Rich Plasma Practical Use in Non-Surgical Musculoskeletal Pathology. In: Lana JF (ed), Platelet-Rich Plasma Regenerative Medi‐ cine: Sports Medicine, Orthopedic, and Recovery of Musculoskeletal Injuries, Spring‐

[25] Weibrich G, Kleis WKG, Hafner G, Hitzler WE. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Cranio Maxillofa‐

[26] Everts PAM, Devilee RJJ, Brown-Mahoney C, Eeftinck SM, Box HAM, Knape JTA, Van Zundert A. Platelet gel and fibrin sealant reduce allogenic blood transfusions

[27] Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF).

and in total knee arthroplasty. Acta Anaesth Scand. 2006;50:593–599.

Wound Ostomy Continense Nurse Society, St Louis, Mo, June 2010.

cal stimulation. Acta Orthop Scand. 2006;77:806–812.

1365-2141.2008.06999.x. Epub 2008 Feb 12.

White. 2001; Accessed 23 Mar 2013.

er. 2014;187-199. DOI: 10.1007/978-3-642-40117-6.

Dent. 2001;10(8):225–228.

cial Surg. 2002; 30(2):97–102.

edn. Academic Press, Elsevier, Burlington. 2007;117–134.

jbc.R109.013219.

188 Immunopathology and Immunomodulation


covery of Musculoskeletal Injuries, Springer. 2014;1-47. DOI: 10.1007/978-3-642-40117-6.


[52] Carter MJ, et al. Use of platelet-rich plasma gel on wound healing: A systematic re‐ view and meta-analysis. J Plast Surg. 2011;15(11):382–410.

covery of Musculoskeletal Injuries, Springer. 2014;1-47. DOI:

[39] Lorenz HP, Longaker MT. Wounds: Biology, pathology, and management. In: Nor‐ ton JA, Bollinger RR, Chang AE, et al (eds) Surgery: basic science and clinical evi‐

[40] Minami T, Horiuchi K, Miura M, et al.Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem. 2004;279(48):50537–

[41] Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament

[42] Bennett SP, Griffiths GD, Schor AM, et al. Growth factors in the treatment of diabetic

[43] Boros P, Miller CM. Hepatocyte growth factor: A multifunctional cytokine. Lancet.

[44] Kosai K, Matsumoto K, Fukanoshi H, et al. Hepatocyte growth factor prevents endo‐ toxininduced lethal hepatic failure in mice. Hepatology. 1990;30(1):151–159.

[45] Matsumoto K, Nakamura T. Hepatocyte growth factor: Molecular structure, roles in liver regeneration, and other biological functions. Crit Ver Oncog. 1992;3(1–2):27–54.

[46] Miyazawa T, Matsumoto K, Ohmichi H, et al. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: A novel

[47] Yuan T, Zhang C-Q Tang M-J, Shang-Chun Guo S-C, Zeng B-F. Autologous plateletrich plasma enchances healing of chronic wounds.Wounds. 2009;21(10):138-141.

[48] Cancela AM, Lana JF, Annichino-Bizzachi JM, Belangero WD,Luzo ACM. Use of Pla‐ telet-Rich Plasma (PRP) in Treating Chronic Wounds. In: Lana JF(ed), Platelet-Rich Plasma Regenerative Medicine: Sports Medicine, Orthopedic, and Recovery of Mus‐

culoskeletal Injuries, Springer. 2014;281-288. DOI: 10.1007/978-3-642-40117-6.

[49] Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic

[50] Zhu Y, Yuan M, Menq HY. Basic science and clinical application of platelet-rich plas‐ ma for cartilage defects and osteoarthritis: A review. Osteoarthritis Cartilage.

[51] Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, et al. Why the platelet-rich gel has anti‐ microbial activity? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103(3):

2013;21(11):1627-37. DOI: 10.1016/j.joca.2013.07.017. Epub 2013 Aug 7.

neurotrophic factor. J Cereb Blood Flow Metab. 1998;18(4):345–348.

wounds. Transfus Apheres Sci. 2004;30:145–151.

10.1007/978-3-642-40117-6.

190 Immunopathology and Immunomodulation

dence, Springer, New York. 2001;77–88.

50554. DOI: 10.1074/jbc.M406454200.

healing. Sports Med. 2003;33(5):381–394.

foot ulcers. Br J Surg. 2003;90(2):133–146.

1995;345(8945):239–5.

303–305.


[77] Sanchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intraarticular injection of an au‐ tologous preparation rich in growth factors for the treatment of knee OA: A retro‐ spective cohort study. Clin Exp Rheumatol. 2008;26(5):910–913.

[66] Hunziker EB. Articular cartilage repair: Basic science and clinical progress. A review

[67] Biggi F, Caloprisco G, Scorrano A. Autologous platelet gel in orthopaedics and trau‐

[68] Kasten P, Beverungen M, Lorenz H, Wieland J, Fehr M, Geiger F. Comparison of pla‐ teletrich plasma and VEGF-transfected mesenchymal stem cells on vascularization and bone formation in a critical-size bone defect. Cells Tissues Organs. 2012;196(6):

[69] Kasten P, Vogel J, Beyen I, et al. Effect of platelet-rich plasma on the in vitro prolifer‐ ation and osteogenic differentiation of human mesenchymal stem cells on distinct calcium phosphate scaffolds: The specific surface area makes a difference. J Biomater

[70] Hunziker EB, Driesang IM, Morris EA. Chondrogenesis in cartilage repair is induced by members of the transforming growth factor-beta superfamily. Clin Orthop Relat

[71] Kon E, Filardo G, Presti ML et al. Utilization of platelet-derived growth factors for the treatment of cartilage degenerative pathology. Paper presented at the Interna‐ tional Cartilage Repair Society Meeting, Electronic Poster Presentation 29.3. Warsaw,

[72] Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: Intra articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Trau‐ matol Arthrosc. 2010;18:472–479. DOI: 10.1007/s00167-009-0940-8. Epub 2009 Oct 17.

[73] Qi YY, Chen X, Jiang YZ, et al. Local delivery of autologous platelet in collagen ma‐ trix simulated in situ articular cartilage repair. Cell Transplant. 2009;18(10):1161–

[74] Da Silva RT, Heidrich F. Therapy with Use of Platelet-Rich Plasma in Orthopedics and Sports Traumatology: Literature Review, Evidence and Personal Experience. In: Lana JF (ed), Platelet-Rich Plasma Regenerative Medicine: Sports Medicine, Orthope‐ dic, and Recovery of Musculoskeletal Injuries, Springer. 2014;153-168. DOI:

[75] Patel S, Dillon MS, Agarwall S, Marwaha M, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis. Am J Sports Med.

[76] Weyrich AS, Lindemann S, Zimmerman GA.The evolving role of platelets in inflam‐ mation. J Thromb Haemost. 2003;1(9):1897–1905. DOI: 10.1046/j.

1169. DOI: 10.3727/096368909X12483162197169. Epub 2009 Aug 5.

2013;41(2):356-364. DOI: 10.1177/0363546512471299. Epub 2013 Jan 8.

of the current status and prospects. Osteoarthr Cartil. 2002;10(6):432–463.

matology (3-year experience). J Bone Joint Surg. 2004;87(Suppl 2):173.

523–533. DOI: 10.1159/000337490. Epub 2012 Jul 10.

Res. 2001; 391(suppl):171–181.

Poland, October 2007.

192 Immunopathology and Immunomodulation

10.1007/978-3-642-40117-6.

1538-7836.2003.00304.x.

Appl. 2008;21(4):386–389. DOI: 10.1177/0885328207088269


Platelet-rich plasma versus corticosteroid injection with a 1-year. Am J Sports Med. 2010;38:255. DOI: 10.1177/0363546509355445.


spective, randomized, multicenter study. J Bone Joint Surg Am. 1999;81(11):1580– 1588.

[102] Sánchez M, Anitua E, Azofra J, et al. Comparison of surgically repaired achilles ten‐ don tears using platelet-rich fibrin matrices. Am J Sports Med. 2007;February;35(2): 245–251.

Platelet-rich plasma versus corticosteroid injection with a 1-year. Am J Sports Med.

[89] Jo CH, Kim JE, Yoon KS, Shin S. Platelet-rich plasma stimulates cell proliferation and enhances matrix gene expression and synthesis in tenocytes from human rotator cuff tendons with degenerative tears. Am J Sports Med. 2012;40(5):1035–1045. DOI:

[90] Chen L, Dong SW, Liu JP, Tao X, Tang KL, Xu JZ. Synergy of tendon stem cells and platelet-rich plasma in tendon healing. J Orthop Res. 2012;30(6):991–997. DOI:

[91] Eliasson P, Fahlgren A, Pasternak B. Unloaded rat Achilles tendons continue to grow, but lose viscoelasticity. J Appl Physiol. 2007;103:459–463. Epub 2007 Apr 5. [92] Wei W, Chen F, Liu Y, et al. Autologous injectable tissue-engineered cartilage by us‐ ing platelet-rich plasma: Experimental study in a rabbit model. J Oral Maxillofac

[93] Sánchez M, Azofra J, Aizpurua B, et al. Use of autologous plasma rich in growth fac‐

[94] Radice F, Yánez R, Gutiérrez V, et al. Comparison of magnetic resonance imaging findings in anterior cruciate ligament grafts with and without autologous platelet-de‐ rived growthfactors. Arthroscopy. 2010;26(1):50–57. DOI: 10.1016/j.arthro.

[95] Mei-Dan O, Mann G, Maffulli N. Platelet-rich plasma: Any substance into it? Br J

[96] Orrego M, Larrain C, Rosales J, et al. Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. Arthroscopy. 2008;24:1373–

[97] Sampson S, Gerhardt M, Mandelaum B. Platelet-rich plasma injection grafts for mus‐ culoskeletal injuries: A review. Curr Rev Musculoskelet Med. 2008;1:165–174. DOI:

[98] Shen W, Li Y, Zhu J, Huard J. Interaction between macrophages, TGFbeta1, and the COX-2 pathway during inflammatory phase of skeletal muscle healing after injury. J

[99] Silva A, Sampaio R. Anatomic ACL reconstruction: Does the platelet-rich plasma ac‐ celerate tendon healing? Knee Surg Sports Traumatol Arthrosc. 2009;17(6):676–682.

[100] Everts PAM, Knape JTA, et al. Platelet-rich plasma and platelet gel, a review. J Extra

[101] Levy O, Martinowitz U, Oran A, et al. The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A pro‐

2010;38:255. DOI: 10.1177/0363546509355445.

10.1177/0363546512437525. Epub 2012 Feb 23.

Surg. 2007; 65:1951–1957. DOI:/10.1016/j.joms.2006.11.044.

tors in arthroscopic surgery. Cuader Artroscopia. 2003;10:12–19.

Sports Med. 2010;44(9):618–619. DOI:10.1136/bjsm.2009.067108.

10.1002/jor.22033. Epub 2011 Dec 12.

2009.06.030.

194 Immunopathology and Immunomodulation

1380.

10.1007/s12178-008-9032-5.

Cell Physiol. 2008;214(2):405–412.

Corpor Techn. 2006;38:174–187.

DOI: 10.1007/s00167-009-0762-8. Epub 2009 Mar 14.

